EP1658089A4 - Compositions for treating pathologies that necessitate suppression of gastric acid secretion - Google Patents

Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Info

Publication number
EP1658089A4
EP1658089A4 EP04769171A EP04769171A EP1658089A4 EP 1658089 A4 EP1658089 A4 EP 1658089A4 EP 04769171 A EP04769171 A EP 04769171A EP 04769171 A EP04769171 A EP 04769171A EP 1658089 A4 EP1658089 A4 EP 1658089A4
Authority
EP
European Patent Office
Prior art keywords
necessitate
suppression
compositions
gastric acid
acid secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769171A
Other languages
German (de)
French (fr)
Other versions
EP1658089A2 (en
Inventor
Ayelet David
Sabina Glozman
Lada Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vecta Ltd
Original Assignee
Vecta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US49793003P priority Critical
Priority to US54431804P priority
Application filed by Vecta Ltd filed Critical Vecta Ltd
Priority to PCT/IB2004/002745 priority patent/WO2005020879A2/en
Publication of EP1658089A2 publication Critical patent/EP1658089A2/en
Publication of EP1658089A4 publication Critical patent/EP1658089A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
EP04769171A 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion Withdrawn EP1658089A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US49793003P true 2003-08-27 2003-08-27
US54431804P true 2004-02-17 2004-02-17
PCT/IB2004/002745 WO2005020879A2 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Publications (2)

Publication Number Publication Date
EP1658089A2 EP1658089A2 (en) 2006-05-24
EP1658089A4 true EP1658089A4 (en) 2007-03-14

Family

ID=34278571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769171A Withdrawn EP1658089A4 (en) 2003-08-27 2004-08-25 Compositions for treating pathologies that necessitate suppression of gastric acid secretion

Country Status (8)

Country Link
EP (1) EP1658089A4 (en)
JP (1) JP2007503427A (en)
KR (1) KR20060083198A (en)
AU (1) AU2004268446A1 (en)
CA (1) CA2536906A1 (en)
IL (1) IL173944D0 (en)
RU (1) RU2006109357A (en)
WO (1) WO2005020879A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663282A4 (en) * 2003-09-24 2007-09-19 Vecta Ltd Oral compositions for the stimulation of gastric acid secretion comprising pentagastrin
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
CN101389316A (en) * 2005-12-28 2009-03-18 武田药品工业株式会社 Controlled release solid preparation
BRPI0620788A2 (en) * 2005-12-28 2011-11-22 Takeda Pharmaceutical Solid preparation
KR101489370B1 (en) 2006-07-25 2015-02-03 벡타 리미티드 Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi
CA2694602A1 (en) * 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
JPH04247026A (en) * 1991-01-31 1992-09-03 Teikoku Seiyaku Co Ltd Oral agent disintegrating in lower part of digestive tract
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2004034957A2 (en) * 2002-10-14 2004-04-29 Vecta Ltd. Methods for treatment of helicobacter pylori-associated disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
BR9915442A (en) * 1998-11-17 2001-08-07 Hickory Specialties Inc A method for covering a food product with collagen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910021A (en) * 1985-11-29 1990-03-20 R. P. Scherer Corporation Targeted enternal delivery system
JPH04247026A (en) * 1991-01-31 1992-09-03 Teikoku Seiyaku Co Ltd Oral agent disintegrating in lower part of digestive tract
WO2001010405A1 (en) * 1999-08-04 2001-02-15 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
WO2004034957A2 (en) * 2002-10-14 2004-04-29 Vecta Ltd. Methods for treatment of helicobacter pylori-associated disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199242, Derwent World Patents Index; AN 1992-343803, XP002414819 *
KATHLEEN PARFITT (ED): "Martindale The Complete Drug Reference", 1999, PHARMACEUTICAL PRESS, LONDON, GB, ISBN: 0 85369 429 X, ISSN: 0263-5364, XP002409837 *

Also Published As

Publication number Publication date
JP2007503427A (en) 2007-02-22
KR20060083198A (en) 2006-07-20
WO2005020879A2 (en) 2005-03-10
WO2005020879A3 (en) 2005-05-19
IL173944D0 (en) 2006-07-05
AU2004268446A1 (en) 2005-03-10
RU2006109357A (en) 2007-10-10
CA2536906A1 (en) 2005-03-10
EP1658089A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
DK1644021T3 (en) Methods and compositions for the treatment of gastrointestinal diseases
DK1628530T3 (en) Methods and compositions for prevention and treatment of sepsis
DE60331236D1 (en) Oral compositions for the treatment of diabetes
DE60131924D1 (en) Process for the preparation of precipitated calcium carbonate compositions
DK1506041T3 (en) Inbandronic acid for the treatment and prevention of osteoporosis
IL178730D0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
PL2077902T3 (en) Use of nutritional compositions for preventing visceral adiposity
HK1081186A1 (en) Pyrazole compositions useful as inhibitors of gsk-3
GB0118749D0 (en) Water treatment compositions
EP1628654A4 (en) Compounds and methods for delivery of prostacyclin analogs
EP1853295A4 (en) Methods and compositions for the treatment of gastrointestinal disorders
DE60335560D1 (en) Compositions containing citric acid for the treatment of nail plug diseases
IL181896D0 (en) Methods and compositions for the treatment of hyperlipidemia
HK1081525A1 (en) Process for the preparation of diisocyanates
IL166274D0 (en) Compositions and methods for sirna inhibition of angiogenesis
SI1567193T1 (en) Colon cleansing compositions
IL157734D0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
ZA200704909B (en) Method of treatment or prophylaxis
IL186578D0 (en) Compositions for treatment of neovascularization diseases
EP1469810A4 (en) Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
ZA200610055B (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
PT1545226E (en) Method of fractionating dairy compositions
ME01493B (en) Lndolidone derivatives for the treatment or prevention of fibrotic diseases
RU2005127058A (en) Methods and compositions for the treatment of gastrointestinal disorders
IL177772D0 (en) Methods and compositions for the treatment of gastrointestinal disorders

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

17P Request for examination filed

Effective date: 20051017

DAX Request for extension of the european patent (to any country) deleted
RIC1 Classification (correction)

Ipc: A61K 38/08 20060101ALI20070124BHEP

Ipc: A61K 45/06 20060101AFI20070124BHEP

Ipc: A61K 31/4439 20060101ALI20070124BHEP

Ipc: A61P 1/04 20060101ALI20070124BHEP

Ipc: A61K 47/00 20060101ALI20070124BHEP

Ipc: A61K 9/00 20060101ALI20070124BHEP

A4 Despatch of supplementary search report

Effective date: 20070207

RIN1 Inventor (correction)

Inventor name: DAVID, AYELET

Inventor name: PAUL, LADA

Inventor name: GLOZMAN, SABINA

17Q First examination report

Effective date: 20080208

18D Deemed to be withdrawn

Effective date: 20080301